Product Introduction
Bioactivity


英文名: Xanthine oxidase-IN-4

描述: Xanthine oxidase-IN-4 (化合物 19a) 是一种具有口服活性的有效黄嘌呤氧化酶 (XO) 抑制剂，IC50值为0.039 μM，可用于高尿酸血症和痛风的研究。Xanthine oxidase-IN-4 在氧嗪酸钾诱导的高尿酸血症大鼠中表现出降尿酸能力。

体外活性: Xanthine oxidase-IN-4 (compound 19a) (1 nM-10 μM, 15 min) exhibits a strong XO inhibitory potency, with an IC 50 of 0.039 μM, and Ki of 0.0037 μM [1].

体内活性: Xanthine oxidase-IN-4 (compound 19a) (SD rats, 10 mg/kg, Intragastrically, once) significantly reduces the serum concentration of uric acid [1]. Animal Model: Sprague-Dawley rats (Six weeks, male, 180-200g, six groups) [1] Dosage: 10 mg/kg Administration: Intragastrically, once Result: Significantly reduced the serum concentration of uric acid, with AUC (uric acid, 1-5 h) of 44.3%.

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year